A recent study concluded that serum prostate specific antigen (PSA)-based screening is beneficial for reducing the lethality of PCa, but was also associated with a high risk of 'overdiagnosis'. Nevertheless, also PCa patients who suffered from organ confined tumors and had negative bone scans succumb to distant metastases after complete tumor resection. It is reasonable to assume that those tumors spread to other organs long before the overt manifestation of metastases. Our current results confirm that prostate tumors are highly heterogeneous. Even a small subpopulation of cells bearing BRCA1 losses can initiate PCa cell regional and distant dissemination indicating those patients which might be at high risk of metastasis.
Introduction
Prostate cancer (PCa) is one of the most frequent types of tumors in high-income countries. Its frequently observed multifocality (ca. 80% of cases) and biological heterogeneity hamper significantly both diagnosis and treatment. It is believed that only a certain subpopulation of cancer cells is related to PCa aggressiveness and accounts for its progression. Therefore, a relevant diagnostic tool defining a subclone of invasive cells is urgently required. A recent study showed that standard serum prostate specific antigen (PSA)-based screening is beneficial for reducing the lethality of PCa, but is also associated with a high risk of 'overdiagnosis' (1) . On the other hand, some PCa patients who suffer from organ confined tumors and have negative bone scans succumb to distant metastases after complete tumor resection. It is reasonable to assume that those tumors had gained the ability of migration, disseminate to regional lymph nodes (LNs) and even bones long before the overt manifestation of metastases. Thus, one promising approach to the early identification of patients at high risk of PCa metastasis is determination of molecular signatures of primary foci associated with lymph node metastasis (LNM) and/or biochemical recurrence (BR) and subsequent detection of circulating tumor cells (CTCs) (2) .
In a previous profiling study based on allelic imbalances (AI) analysis of CTCs isolated from peripheral blood of PCa patients and a small cohort of corresponding primary tumor foci, AIs of 9 loci were observed in a fraction of CTCs. Intriguing, the BRCA1 AI was found in four of five cases where BR occurred within three years after a prostatectomy (3) . It was hypothesized that haploinsufficiency of the BRCA1 gene in even a small subclone of tumor cells is associated with the occurrence of CTCs in the patients' peripheral blood as well as early BR of PCa and hence might account for metastasis formation.
The BRCA1 protein acts as a prominent tumor suppressor and due to its 'canonical', but yet largely unknown functions in cell cycle regulation and homologous recombination, is a key player in cellular control systems (4) . The clinical relevance of BRCA1 alterations is well-documented in both hereditary and sporadic breast and ovarian cancers (5).
However, BRCA1 deficiency or AIs were also observed in some other types of tumors (6) (7) (8) and corresponded to a worsened survival (6, 7) . The germline BRCA1 mutations were already reported to indicate a higher risk of PCa and its more aggressive phenotype (9) (10) (11) . BRCA1 AIs were also detected in approx. 13-46% of tested cases of sporadic PCa (12) (13) (14) (15) . They coincided frequently with the AIs of other loci on chr17q21 and, to the best of our knowledge, only in one study were associated with the higher PCa stage (14) . These AI analyses were conducted on the very low number of cases (23-25 samples) and did not exclude the possibility that alterations of another tumor suppressor gene located on 17q21 can play a pivotal role in prostate tumorigenesis.
Therefore, the aim of this study was to investigate whether distinct BRCA1 alterations or larger rearrangements of chr17q12-21 may serve as a potential signature of progression in sporadic PCa. The BRCA1 gene locus, a gene rich region located on 17q21 proximal of the BRCA1 gene (17q GRR) and ERBB-2/HER-2 were analysed in primary tumors, lymph nodes and CTCs and compared to the clinical staging, grading, and outcome. At the Department of Urology, University Medical Centre, Hamburg-Eppendorf, Germany, 20 ml of peripheral blood from seven unrelated patients with metastatic PCa and three healthy volunteers was collected into EDTA tubes and processed for CTC enrichment within three hours after phlebotomy as described (17) . AI analysis DNA isolation, microsatellite-sequence-based PCR and AI analysis of locus D17S855 (BRCA1) and D10S541 (PTEN) were performed as described (3). Fig. 1A-B ).
Materials and Methods

Patients
Methylation assay
BRCA1 losses and gains occurred in 18 (14%) and 5 (7%) of patients, respectively. The showed lack of methylation in all 31 PCa cases. Two other loci on chromosome 17q
(17q GRR and ERBB-2/HER-2) were analyzed to investigate whether BRCA1 alterations are limited to BRCA1 or caused by larger alterations of chromosome 17q.
The BRCA1 gains were found restricted to the gene locus. On the contrary, BRCA1
losses coexisted in 71% of the cases with the loss of 17q GRR containing genes already proposed to be involved in tumorigenesis, e.g. BECN1, EZH1 and VPS25 ( Fig. 2A ). In addition, BRCA1 losses appeared to be prognostically significant in multivariate analysis (p = 0.048, Fig. 2B ). However, the Cox Regression model was done on a relatively small group of patients and needs to be confirmed on a larger cohort. (Fig. 3A, B ).
BRCA1 aberrations in prostate cancer
Applying the strategy in which the frequency of cells with BRCA1 losses was counted in 500 randomly selected cells and compared to the indices of false-hybridization obtained in the normal healthy volunteers, significantly elevated number of cells with BRCA1 loss were found in 4 of 7 patients (p < 0.05). Of note is that both Vim staining and scoring method helped to point out the cells, particularly, when the pattern two BRCA1 copies :
three CEP17 copies was observed (Fig. 3B) . Such a genotype was rarely detectable in the blood of healthy volunteers. The clinically established parameters such as T and N status showed that the cells bearing BRCA1 losses in PCa seem to be efficient to penetrate LN, possibly survive the stress conditions in blood stream and consequently might invade distant organs.
Determination of PTEN gene dosage Another tumor suppressor gene PTEN is
reported to be lost in both primary PCa (22) and a majority of prostate CTCs (3) which is also believed to be one of the initiating neoplastic events during prostate tumorigenesis in mice (23) . In the current study, PTEN gene dosage was analyzed in a fraction of PCa and LNM and compared with the status of BRCA1 gene. The AI of PTEN paralleled BRCA1 losses and gains, but was also found in cases with normal BRCA1 gene dosage both in 31 tested primary PCa and 11 corresponding pairs PCa-LNM (Tab. 2, S3). This observation leads to the conclusion that PTEN losses always underlie BRCA1 losses but not vice versa.
Discussion
The high prevalence of prostate cancer in the male population needs accurate diagnostic tools early designating patients at risk of progression. The so-far used PSA screening copes with this challenge only partially (1), hence the characterization of new progression markers seem to be urgently required. In a previous study including 9 loci, it was found that a fraction of CTCs delivered from one, even very small focus, bears BRCA1 AIs and may be associated with early BR after radical prostatectomy (3). In order to evaluate the biological and clinical impact of this phenomenon, we performed Unlike in sporadic breast cancer where BRCA1 methylation is a frequent event (25), BRCA1 promoter was not methylated in any analyzed PCa sample including the ones with the detected BRCA1 loss or gain. It suggests that BRCA1 can be haploinsufficient as it was observed already in breast and ovarian cancer (26, 27) .
In more than 70% of cases, a simultaneous loss of BRCA1 and the 17q GRR locus was observed. At this locus, at least 3 genes can hypothetically amplify the effect of BRCA1 loss: BECN1 involved in autophagy (19) , EZH1 responsible for epigenetic processes in prostate tumorigenesis and a subsequent loss of BRCA1 can enhance its effect. It might be hypothesized that PTEN AI and other factors lead to an increased activation of the Akt pathway (32) . As one option of explanation it might result in impairment of BRCA1-and RAD51-driven homologous recombination by retention of these proteins in the cytoplasm (33) . One may speculate that defects of homologous recombination generate different chromosomal aberrations among others a loss of BRCA1, which promotes further tumorigenesis and triggers PCa dissemination (Fig. 4) , e.g. in an EMTmimicking way.
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